Overview

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (CLL).
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Treatments:
Navitoclax